Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety of ADSC-SVF-002 in Soft Tissue Defects and Abnormal Wound Healing
NCT02590042Phase 1Unknown
- Sponsor
- AdiSave
- Start
- Oct 2017
- Primary completion
- Oct 2020
- Modality
- Mesenchymal Stem Cells
- Countries
- 1
01
Overview
Phase 1, open-label, single-arm trial of ADSC-SVF-002 in soft tissue defect, Abnormal wound healing and Severe cutaneous adverse drug reactions (SCARs), sponsored by AdiSave. Primary endpoint: Continuous monitoring of safety via laboratory tests and physical examinations at 6 months. Status: unknown.
02
Drugs
ADSC-SVF-002
03
Conditions
soft tissue defectAbnormal wound healingSevere cutaneous adverse drug reactions (SCARs)
Beyond the preview
Go deeper on NCT02590042.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02590042.